A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension

BACKGROUND: Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD). OBJECTIVE/METHODS: We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titra...

Descripción completa

Detalles Bibliográficos
Autores principales: Cushman, William C., Bakris, George L., White, William B., Weber, Michael A., Sica, Domenic, Roberts, Andrew, Lloyd, Eric, Kupfer, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
ORIGINAL PAPERS: Therapeutic aspects
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862000/
https://www.ncbi.nlm.nih.gov/pubmed/29334491
http://dx.doi.org/10.1097/HJH.0000000000001647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5862000/
https://www.ncbi.nlm.nih.gov/pubmed/29334491
http://dx.doi.org/10.1097/HJH.0000000000001647

Ejemplares similares